Impact of temporary storage conditions on the viability of *Streptococcus pneumoniae* in saliva

Orchid M. Allicock[1†], Anna York, Pari Waghela, Devyn Yolda-Carr,

Daniel M. Weinberger, Anne L. Wyllie

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Ct 06510, USA

[†]Correspondence: Orchid M. Allicock (orchid.allicock@yale.edu)

Abstract

Nasopharyngeal swabs are considered the gold standard sample type for the detection of *Streptococcus pneumoniae* carriage, but recent studies have demonstrated the utility of saliva in improving carriage detection in adults. Saliva is generally collected in its raw, unsupplemented state, unlike nasopharyngeal swabs, which are collected into stabilizing transport media. Little data exist regarding the stability of pneumococcus in unsupplemented saliva during transport and laboratory storage. We therefore evaluated the effect of storage conditions on the detection of pneumococcus in saliva samples using strains representing eight pneumococcal serotypes. The bacteria were spiked into raw saliva from asymptomatic individuals, and we assessed sample viability after storage for up to 72 hours at 4°C and room temperature as well as following three freeze-thaw cycles. We observed little decrease in pneumococcal detection following culture-enrichment and qPCR detection of genes *piaB* and *lytA* when compared to testing fresh samples, indicating prolonged viability of pneumococcus in neat saliva samples. This sample stability makes saliva a viable sample type for pneumococcal carriage studies conducted in remote or low resource settings, and provides insight into the effect of storage of saliva samples in the laboratory.

Introduction

Streptococcus pneumoniae (pneumococcus) is among the most frequent causes of severe pneumonia and pneumonia deaths in the United States (1). However, pneumococcus is also a commensal organism that resides asymptomatically in the upper respiratory tract of healthy individuals. In susceptible individuals, pneumococcus can become pathogenic under certain circumstances. Pneumococcus is the causative agent of otitis media, sinusitis and pneumonia as well as invasive pneumococcal diseases (IPD), such as meningitis and sepsis. The rate of morbidity and mortality for serious pneumococcal disease is highest in young children, older adults, and immunocompromised individuals (2). Case fatality rates range up to 20% for sepsis and 50% for meningitis in lower and middle income countries (3). Following the introduction of pneumococcal conjugate vaccines (PCV) 7 and 13 (PCV7 and PCV13), both asymptomatic carriage and IPD caused by vaccine serotypes declined. However, there was a concomitant increase in the prevalence of non-vaccine serotypes (NVTs), known as serotype replacement (4-6). Post-vaccine studies have provided insights into the shift in frequency of vaccine and non-vaccine serotypes in both carriage and disease (7-10). However, continued large-scale surveillance is needed to monitor the changing serotype landscape in order to better inform the development of next-generation vaccines.

Nasopharyngeal swabs have long been considered the gold-standard sample type for detection of carriage of pneumococcus in young children, however detecting carriage in adults is more challenging. In 2013, the WHO advised the additional collection of oropharyngeal swabs in older adults (11), although false-positivity from other oral streptococci may be problematic (12). Due to their invasive nature, nasopharyngeal swabs are generally not well tolerated, and sample collection requires a healthcare worker. This can restrict or prevent sampling of specific populations, particularly the elderly or disabled or individuals in low-resource settings with

minimal access to healthcare. Therefore, alternative, less-invasive sample types, which can be

collected without the need for healthcare workers, are important for the study of pneumococcal

carriage in these populations.

The use of nasopharyngeal swabs for pneumococcal carriage studies during the COVID-19

pandemic was associated with safety and supply chain issues. Non-essential in-person visits

with healthcare workers were restricted due to safety concerns. Additional supply chain issues

reduced access to materials required for nasopharyngeal and oropharyngeal sampling, further

hampering attempts to continue carriage studies. These complications provided the impetus for

pneumococcal carriage studies to move away from swab-based sampling and utilize alternative

sample types. Saliva has been shown to be a sensitive sample type for detection of

pneumococcal carriage in individuals of all ages (13-15). Saliva sampling is non-invasive and

can be collected quickly and easily in the home without a healthcare worker. However, at-home

sample collection brings about potential issues with short-term storage, collection and transport

of the samples to the lab. In order to reap the benefits of using saliva samples for studies of

pneumococcal carriage, more data are needed about how variations in storage conditions and

time from sample collection to laboratory processing may impact detection and viability of

pneumococcus in these samples.

In this study, we evaluated the viability of pneumococcus in saliva over extended periods (24, 48

and 72 hours) when stored at either 4°C or room temperature. We also investigated the viability

of pneumococcus after a series of freeze-thaw cycles at -20ºC and -80ºC, with and without

glycerol supplementation to evaluate best practices for storage and processing of saliva

samples in the laboratory. Understanding the stability of pneumococcus in saliva is also

particularly important for carriage studies being conducted in remote regions or in resource-

limited settings where quick transport or access to cold storage may not be readily available.

Methods

Ethics statement

Deidentified saliva samples were collected from healthy adult volunteers who were

asymptomatic for respiratory infection. Potential study participants were informed in writing

about the purpose and procedure of the study and consented to study participation through the

act of providing a saliva sample; the requirement for written informed consent was waived by the

Institutional Review Board of the Yale Human Research Protection Program (HIC

#2000029374).

Saliva samples

Saliva samples were collected from healthy volunteers according to previously published

protocols (15). Participants were asked to drool saliva into a 15 mL polypropylene tube at least

one hour after their last meal or drink, these saliva samples were considered whole mouth

unstimulated saliva. Samples were transferred at room temperature to the laboratory for

temporary storage at 4ºC and stored within 12 hours at -80ºC.

Sample processing

To confirm the status of each saliva sample (i.e. pneumococcus positive or negative), 50 μl of

saliva was heated for 10 mins at 95°C, and a qPCR targeting *piaB* and *lytA* was conducted (as

described below). Saliva samples that were qPCR-negative for *piaB* were considered

pneumococcal negative and were stored at -20ºC until required for spiking experiments.

Table 1 Strains of *Streptococcus pneumoniae* used in this study

Strain	Serotype	Source
ABC020026160	3	CDC
ABC020012001	4	CDC
ABC020024416	5	CDC
ABC020025076	6C	CDC
ABC010005954	7F	CDC
ABC010001831	9V	CDC
ABC020009080	11A	CDC
#64Israel	19F	*(16)*

Bacterial Isolates

Pneumococcal isolates from our collection (Table 1) were selected to represent eight different representative serotypes (3, 4, 5, 6C, 7F, 9V, 11A, 19F). These isolates were cultured on TSA II + 5% (v/v) defibrinated sheep blood (blood plates) and incubated at 37⁰C with 5% CO_2 overnight. Serotypes were confirmed using IMMULEX™ pneumococcus antisera per the manurfacturer's instructions. The isolates' lawn was harvested into brain heart infusion (BHI) media supplemented with 10% (v/v) glycerol (BHI+10% glycerol) using a cotton swab and was stored at -80⁰C for spiking. The colony forming units per mL (CFU/mL) of each sample was determined by colony counting of serially diluted samples, cultured on blood plates and incubated at 37⁰C and 5 % CO_2 overnight.

Experimental Design

For each isolate listed in **Table 1**, the spiked-saliva experiments were conducted at 10^3 and 10^4 CFU/mL which are clinically relevant for saliva samples in children (Wyllie et al. 2014; York et al. 2022) . To determine the stability of pneumococcus over time, spiked and clinical saliva samples

were incubated at room temperature (~20ºC) or 4ºC. At 24 hours, 48 hours and 72 hours, the

spiked-saliva samples were vortexed, and 100 µl were removed from each sample for culture-

enrichment.

To determine the effect of freeze-thawing on the stability of pneumococcus, aliquots of spiked-

saliva (10^3 and 10^4 CFU/mL), with and without the addition of 10% glycerol, were stored for a

minimum of 2 hours at -20ºC or -80ºC, before being thawed to room temperature. Once each of

the aliquots was thawed, the samples were vortexed, and 100 µl were removed from each

sample for culture-enrichment before the remainder was returned to -20ºC or -80ºC. This

process was repeated twice more.

Culture enrichment of saliva

At each of the study time points, 100 µl of spiked saliva or clinical saliva was plated on TSA II +

5% (v/v) defibrinated sheep blood supplemented with 10 µg/mL gentamicin (gent plates) (Krone

et al. 2015), and incubated at 37ºC and 5% CO_2 overnight. The following day, all bacterial

growth was harvested from culture plates into BHI+10% glycerol, and stored at -80ºC until

further analysis. These stored samples were considered to be culture-enriched for pneumococci.

Culture-enrichment of saliva samples at each time-point ensures that Ct values obtained

represent viable pneumococci and not exogenous DNA.

Detection of pneumococcal carriage using the molecular method

Culture-enriched saliva samples were thawed on ice. DNA was extracted from 200 µl of each

sample using the MagMAX Ultra Viral/Pathogen Nucleic Acid Isolation kit (ThermoFisher

Scientific) on the KingFisher Apex (ThermoFisher Scientific) with modifications. Each DNA

template was tested in qPCR for pneumococcal genes *piaB (17, 18)* and *lytA* (19). The assays

were carried out in 20 µl reaction volumes using SsoAdvanced Universal Probe Supermix

(Biorad, USA), primer/probe mixes (Iowa Black quenchers) for *piaB* and *lytA* at final

concentrations of 10 nM and 12 nM respectively, and 2.5 µl of genomic DNA. DNA of *S.*

pneumoniae serotype 19F strain was included as a positive control in every run. Assays were

run on a CFX96 Touch (Biorad) under the following conditions: 95⁰C for 3 minutes, followed by

45 cycles of 98⁰C for 15 seconds and 60⁰C for 30 seconds. Samples were considered positive

for pneumococcus when Ct values for both genes were ≤40 (13).

Colony isolation and serotyping

Clinical samples that were qPCR-positive for *piaB* (pneumococcus-positive), were serially

diluted in phosphate buffered saline, then 100 µl of 10^{-4}, 10^{-5} and 10^{-6} dilutions were plated on

blood plates, and incubated at 37⁰C and 5% CO_2. Following overnight incubation, plates were

screened for single alpha-haemolytic colonies, which were selected, expanded onto new plates,

and tested for optochin sensitivity. Optochin sensitive isolates were serotyped using

IMMULEX™ pneumococcus antisera (SSI Diagnostica, Hillerød, Denmark) per the

manufacturer's instructions.

Statistical analysis

To evaluate the impact of temperature, serotype, number of freeze-thaw cycles and

concentration of spiked bacteria on the recovery of pneumococcus from spiked saliva samples,

linear regression was used. Interaction terms were used to evaluate whether the effect of time,

temperature, or starting concentration varied by strain. ΔCt represented the change in Ct value

from freshly spiked saliva following each condition (categorical). P-values of less than 0.05 were

considered significant. Statistical tests were conducted using R (version 3.5.2) as described in
the figure legends.

Results

171 The viability of pneumococcus in a sample was inferred by the detection of pneumococcal DNA
172 after undergoing sample culture enrichment. Overall, the Ct values obtained for both gene
173 targets *piaB* and *lytA* were concordant (see Tables S1 - S3). For clarity only *piaB* results will be
174 presented and discussed.

Viability of *S. pneumoniae* over time

To examine the viability of *S. pneumoniae* in raw saliva samples at temporary storage
conditions, we measured the concentration of pneumococcal DNA following culture enrichment
by qPCR. When comparing two concentrations of spiked saliva (10^3 and 10^4 CFU/mL),
averaging across all serotypes at time zero, Ct values of spiked saliva at 10^3 CFU/mL were on
average 2.29 higher than those at 10^4 CFU/mL ($p<0.001$) (**Figure 1**). After adjusting for
concentration, there was no significant increase in Ct (which would represent a decline in
bacterial survival) between 0 and 24 hours (ΔCt 1.08, $p=0.12$), however after 48 and 72 hours a
significant increase in Ct value was observed (ΔCt 3.11, $p<0.001$ and ΔCt 3.18, $p<0.001$
respectively). The pneumococci in saliva samples were slightly more stable at 4ºC, but this was
not significant (ΔCt 0.17, $p=0.73$).

Figure 1. Viability of *Streptococcus pneumoniae* after prolonged storage at room temperature or
4ºC. *S. pneumoniae* detection in saliva spiked at 1,000 CFU/mL and 10,000 CFU/mL over a 72-hour time
course when stored at either 4ºC (circles) or room temperature (triangles). Detection of strains
representing each serotype was relatively consistent for up to at least 48 hours. Each point represents
an individual sample. *lytA* values can be found in Table S1.

Figure 2. Viability of *Streptococcus pneumoniae* after freeze-thaw cycles. *S.pneumoniae* detection
in saliva spiked at 1,000 CFU/mL (circles) and 10,000 CFU/mL (triangles) following each over a series of
three freeze-thaw cycles at either -20⁰C or -80⁰C. *lytA* values can be found in Table S2.

Viability of *Streptococcus pneumoniae* after freeze-thaw cycles

Saliva from healthy volunteers were spiked with *S. pneumoniae* at different concentrations, and

after each freeze-thaw cycle, we measured pneumococcus from all the strains tested,

representing eight different serotypes. At both conditions (-20⁰C or -80⁰C) there was no

significant difference in Ct values between fresh saliva and the first freeze-thaw cycle (**Figure 2)**.

However, pneumococcal loss was lower at -80⁰C than at -20⁰C for both cycle 2 (-80⁰C, ΔCt -3.81

p=0.01 vs -20⁰C, ΔCt 3.877, *p*<0.001) and cycle 3 (-80⁰C, ΔCt -4.65, *p*<0.05 vs -20⁰C, ΔCt 5.056,

p<0.001) when compared to fresh saliva. The addition of glycerol to the saliva samples before

storage as a cryoprotectant did not make an impact on survival at any stage, irrespective of

temperature (*p*=0.1). Of the 8 strains tested, the increase in Ct value was most notable for the

isolates with serotype 3, 4 and 6C capsules, where no viable pneumococcus was detected after

cycle 2, 3 or 2 respectively.

Clinical validation

Pneumococcus was detected in the saliva specimens collected from three asymptomatic

volunteers (referred to as P1, P2 and P3). These saliva specimens were aliquoted and

subjected to the conditions outlined previously. The viability of pneumococcus in specimens P1

and P2 (Ct values when tested fresh of 33.04, 19.65 respectively) remained stable over three

freeze-thaw cycles and at both 4⁰C and room temperature over 72 hours (**Figure 3**). However,

for specimen P3 (Ct values when tested fresh of 36.99), pneumococcus was only detected after

the first freeze-thaw cycle, but not thereafter. Detection remained stable at 72 hours at room

temperature, but for only 48 hours at 4⁰C. Notably, there was discordance between Ct values for

piaB and *lytA* (difference of >5 Ct values) in both between *piaB* and *lytA* genes for P2 and P3

specimens, suggesting possible carriage of non-pneumococcal streptococci with a *lytA*

homologue (20-22) or potentially unencapsulated pneumococci (23).

An attempt was made at isolating the pneumococcal colonies. For P2, of the 36 colonies that

were optochin sensitive, 32 were identified to be the majority species belonging to serogroup 4,

and 4/36 were identified to be a minority co-colonizing species belonging to serogroup 15. We

were unable to isolate single colonies of pneumococcus from the other clinical samples using

standard culture-based methods.

Figure 3. Detection of *S. pneumoniae* in clinical samples (P1-3) over **A** three freeze-thaw cycles, and **B**

over a 72-hour time course. We were able to isolate multiple pneumococcal colonies from P2, however

we had difficulty isolating colonies from P1 and P3. Abbreviations: Cy – cycles; H – hours; RT – room

temperature. *lytA* values can be found in Table S3.

Discussion

New PCVs that target different sets of serotypes are in various stages of clinical development

and introduction in the community. Ongoing surveillance of pneumococcus in the community is

necessary to assess the impact of PCVs and to monitor the emergence of non-vaccine

serotypes. Nasopharyngeal swabs and/or oropharyngeal swabs are considered the gold

standard sample type for surveillance, however they have their limitations. They are not well

tolerated due to the discomfort, resulting in many individuals showing reluctance or poor

adherence to sampling protocols. The requirement for a healthcare professional to collect the

sample can cause additional challenges. The COVID-19 pandemic meant that collection of

nasopharyngeal swabs for surveillance studies was difficult, and alternative sample types were

needed urgently. While collection of saliva is sensitive for detection of pneumococcal carriage

(14, 15), the viability of pneumococcus in saliva was previously unknown.

For this study, we selected eight strains, representing eight different serotypes (3, 4, 5, 6C, 7F,

9V, 11A and 19F) with varying degrees of encapsulation and different capsular properties.

Serotypes 4, 11A and 19F represent small, medium and large capsules respectively (24).

Serotype 3 was included in this study due to its clinical significance; it often causes severe

disease, and is able to evade the vaccine induced immune response by releasing its capsule

into the surrounding environment (25). While the majority of serotypes are anionic, serotype 7F

(along with 7A, 14, 33F, 33A, and 37) is uncharged (26, 27) and was therefore also included in

this study. As *piaB* was used to determine the presence of pneumococci in spiked-saliva, and

piaB is absent from the majority of unencapsulated pneumococci (23), we did not include any

unencapsulated isolates in this study. Any future work including the viability of unencapsulated

pneumococci may require alternate gene targets such as SP2020 (22).

For the eight isolates tested, we demonstrated that saliva samples can be stored or transported

at room temperature or 4°C for up to 48 hours (and often longer) without any significant loss of

viability to pneumococcus. All strains of the eight serotypes tested showed no significant loss in

survival over the first 24 hours. Between 24 and 72 hours some decrease in survival was

observed, representing a 10-fold loss in bacterial viability, but all strains were still detected

regardless of starting concentration. Therefore, for the storage and transport of saliva collected

for pneumococcal carriage studies, either room-temperature or refrigeration are feasible.

In contrast, for some strains, multiple freeze-thaw cycles resulted in a decrease or loss of

detection, representing to us an effect on strain viability. Furthermore, we observed no benefit by

use of 10% glycerol as a cryoprotectant in this sample type. For long-term laboratory storage,

samples should be aliquoted to minimize the number of freeze-thaw cycles that occur.

Differences in isolation of pneumococci from the three clinical samples (P1, P2 and P3) were

related to the concentration of pneumococci in the saliva. The Ct value of P2 suggests that the

pneumococcal concentration was between 10^3 and 10^4 CFU/mL whereas both P1 and P3

contain less than 10^1 CFU/mL. Using culture-based methods, pneumococci could easily be

isolated from sample P2 due to its high concentration. Additional enrichment steps, such as

Magnetic Bead-Based Separation may be required for isolation of pneumococci from P1 and P3

due to the reduced pneumococcal concentration and the high concentration of other bacterial

species in saliva (reflected in the high Ct values) (28).

For the first time, this study investigates the viability of pneumococci in raw-unsupplemented

saliva at temporary storage conditions, supporting the use of saliva as a sample type for

pneumococcal carriage. With little difference observed between the strains tested, findings

suggest that pneumococcal survival in saliva may be independent of capsule size and charge.

However, since each serotype is represented by only one isolate, additional studies are

recommended to further investigate this observation at the serotype level. The findings

presented here are particularly important for studies conducted in low-resource settings, rural

areas and for studies conducted in the absence of healthcare professionals and adequate cold-

chain transfer of samples between sampling and processing sites. In addition to being cost

effective, and easy for self-collection, the use of saliva for pneumococcal carriage studies may

increase participant enrollment and retention, which is particularly important for longitudinal

studies. The impact of storage conditions may vary between host saliva and so our work could

be extended to samples from a larger subject population, with differing saliva microbial

communities.

Table S1 Freeze thaw

Table S2 Time course

Table S3 Clinical data

References

1.   Dion CF, Ashurst JV. Streptococcus Pneumoniae Treasure Island (FL): StatPearls Publishing;
2022 [updated 2022/4/30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29261971.
2.   Burman L, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing
factors, and prognosis. Rev Infect Dis. 1985;7(2):133-42.
3.   O'brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease
caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet.
2009;374(9693):893-902.
4.   Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal
vaccination. Lancet. 2011;378(9807):1962-73.
5.   Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, et al. Persistent circulation of
vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent
pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221(8):1361-70.
6.   CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal
conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR
Morb Mortal Wkly Rep. 2005;54(36):893-7.
7.   Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of
Pneumococcal Disease Due to Non–Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United
States during the Era of Widespread PCV7 Vaccination, 1998–2004. J Infect Dis. 2007;196(9):1346-54.
8.   Pelton SI, Loughlin AM, Marchant CD. Seven Valent Pneumococcal Conjugate Vaccine
Immunization in Two Boston Communities: Changes in Serotypes and Antimicrobial Susceptibility
Among: Streptococcus pneumoniae: Isolates. Pediatr Infect Dis J. 2004;23(11):1015.
9.   CDC. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--
eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144-8.
10.   van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MPE, Harrison TG, et al.
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent
pneumococcal conjugate vaccine in England. Vaccine. 2014;32(34):4349-55.
11.   Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, et al. Standard
method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated
recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine.
2013;32(1):165-79.

12.   Boelsen LK, Dunne EM, Gould KA, Ratu FT, Vidal JE, Russell FM, et al. The Challenges of Using
Oropharyngeal Samples To Measure Pneumococcal Carriage in Adults. mSphere. 2020;5(4).
13.   Wyllie AL, Chu MLJN, Schellens MHB, Gastelaars JVE, Jansen MD, Van Der Ende A, et al.
Streptococcus pneumoniae in saliva of Dutch primary school children. PLoS One. 2014;9(7):1-8.
14.   Krone CL, Wyllie AL, Van Beek J, Rots NY, Oja AE, Chu MLJN, et al. Carriage of Streptococcus
pneumoniae in aged adults with influenza-like-illness. PLoS One. 2015;10(3):1-15.
15.   Wyllie AL, Rümke LW, Arp K, Bosch AATM, Bruin JP, Rots NY, et al. Molecular surveillance on
Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation
independent from the reservoir in children. Sci Rep. 2016;6:34888.
16.   Greenberg D, Givon-Lavi N, Faingelernt Y, Ben-Shimol S, Avni YS, Bar-Ziv J, et al.
Nasopharyngeal Pneumococcal Carriage During Childhood Community-Acquired Alveolar Pneumonia:
Relationship Between Specific Serotypes and Coinfecting Viruses. J Infect Dis. 2017;215(7):1111-6.
17.   Trzciński K, Bogaert D, Wyllie A, Chu MLJN, van der Ende A, Bruin JP, et al. Superiority of Trans-
Oral over Trans-Nasal Sampling in Detecting Streptococcus pneumoniae Colonization in Adults. PLoS
One. 2013;8(3):11-3.
18.   Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, Bosch AATM, Groot JA, van Engelsdorp
Gastelaars J, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in
children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep. 2016;6:23809.
19.   Carvalho MdGS, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al. Evaluation
and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of
pneumococcal DNA. J Clin Microbiol. 2007;45(8):2460-6.
20.   Greve T, Møller JK. Accuracy of using the lytA gene to distinguish Streptococcus pneumoniae
from related species. J Med Microbiol. 2012;61(Pt 4):478-82.
21.   Simões AS, Tavares DA, Rolo D, Ardanuy C, Goossens H, Henriques-Normark B, et al. lytA-
based identification methods can misidentify Streptococcus pneumoniae. Diagn Microbiol Infect Dis.
2016;85(2):141-8.
22.   Tavares DA, Handem S, Carvalho RJ, Cristina Paulo A, de Lencastre H, Hinds J, et al.
Identification of Streptococcus pneumoniae by a real-time PCR assay targeting SP2020. Sci Rep.
2019;9(1).
23.   Tavares DA, Simões AS, Bootsma HJ, Hermans PW, de Lencastre H, Sá-Leão R. Non-typeable
pneumococci circulating in Portugal are of cps type NCC2 and have genomic features typical of
encapsulated isolates. BMC Genomics. 2014;15:863.
24.   Weinberger DM, Trzciński K, Lu Y-J, Bogaert D, Brandes A, Galagan J, et al. Pneumococcal
capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5(6):e1000476.
25.   Choi EH, Zhang F, Lu Y-J, Malley R. Capsular Polysaccharide (CPS) Release by Serotype 3
Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies. Clin Vaccine
Immunol. 2016;23(2):162-7.
26.   Kamerling JP. Pneumococcal polysaccharides: a chemical view. Streptococcus pneumoniae:
molecular biology and mechanisms of disease. 1999:81-114.
27.   Lin FL, Vinogradov E, Deng C, Zeller S, Green BA, Jansen KU, et al. Identification of the common
antigenic determinant shared by Streptococcus pneumoniae serotypes 33A, 35A, and 20 capsular
polysaccharides. Carbohydr Res. 2013;380:101-7.
28.   York A, Huynh ET, Mbodj S, Yolda-Carr D, Hislop MS, Echlin H, et al. Magnetic Bead-Based
Separation (MBS) of Pneumococcal Serotypes. bioRxiv. 2022:2021.06.06.447277.
377